Late Breaking Clinical Trial on ACC

Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: - Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial - A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise

Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 Kardia-2 Study - Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy - Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results - Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial - Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial

Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements

Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements. - Fractional Flow Reserve-guided Complete Or Culprit-only PCI In Patients With ST-elevation Myocardial Infarction - Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention In Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, Ivus-acs Trial - A Multicenter Prospective Randomized Study Comparing The Incidence Of Periprocedural Cerebral Embolisms Caused By Catheter Ablation Of Atrial Fibrillation Between Cryoballoon And Radiofrequency Ablation - Protein And Exercise To Reverse Frailty In Older Men And Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial - Transseptal Versus Retrograde Aortic Ventricular Entry To Reduce Systemic Emboli (the TRAVERSE Trial)

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials

Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: - Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Late Breaking Clinical Trial on interventional cardiology

Professor Douglas E. Drachman shared his insights on the Late Breaking Clinical Trial sessions about interventional cardiology trials which he co-moderated. - Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial - One-month Ticagrelor Monotherapy After PCI In Acute Coronary Syndromes: Principal Results From The Double-blind, Placebo-controlled Ultimate Dapt Trial

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV

Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT) - Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery - Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM - A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

Late-Breaking Clinical Trials V

ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials: - Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) - Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial - Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial - Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques - Comparison Of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For The Outcomes Of Drug-coated Balloon In The Treatment Of Femoropopliteal Artery Disease

PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma?

David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels at one month after their last chemotherapy dose compared with those who did not take it, according to results from the PROACT study presented during a Late-Breaking Clinical Trial session at ACC.24 in Atlanta.

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of patients treated with lerodalcibep, versus 16% of those on placebo, attained the newer, more stringent guideline-recommended LDL targets set by the American College of Cardiology and other expert organizations.

Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

Professor Steven E. Nissen shared his insights on the TACTiC study, presented during a Late-Breaking Clinical Trial session at ACC.24. The study proved that the method improves lipid control and adherence.

EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death

Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure or death from any cause among patients with an increased risk for HF following acute myocardial infarction, according to the results of the EMPACT-MI study.

ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI

Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

Study Links E-Cigarette Use with Higher Risk of Heart Failure

Dr. Yakubu Bene-Alhasan shared his insights on the large study that adds to growing body of evidence that vaping may harm the heart. People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure.

Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock

Professor Robert Roswell shared his insights on the DanGer Shock trial. Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology's Annual Scientific Session.

Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials

ACC President B. Hadley Wilson shared his insights on Late-Breaking Clinical Trials I, presented during at ACC.24: - RELIEVE-HF: Does Impact of Interatrial Shunting Differ By HF Type? - EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MI